|
Javelin Pharmaceuticals, Inc. (Javelin) is a specialty pharmaceutical company. It is engaged in the research, development and commercialization of products for the pain management market. The Company develops products optimized for relieving acute moderate-to-severe pain. In addition, the product choices available for the treatment of acute moderate-to-severe pain are limited in the doses that may be given due to side effects, including cardiovascular depression, tolerance and addiction, respiratory depression, constipation, sedation, and general diminution of quality of life. Javelin’s product candidates Dyloject (injectable diclofenac), Ereska (intranasal ketamine) and Rylomine (intranasal morphine) are focused on treating a variety of pain disorders ranging from acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post-operative pain, post-trauma pain, such as orthopedic injury pain, procedural pain and burn pain.
|
|
Around The Net
You are reading news provided by a variety of web sources.
Drug Pipeline
| Drug Name | Type Of Drug | FDA Status | Drug Phase |
| Dyloject |
Pain Management
| Pending Decision | Phase 3 |
Events
FDA Decision:
FDA decision.
(relates to the drug Dyloject)
Add New Event
In order to write a comment you must first login.
Login or Register (for free!)
Add Event
Important Links
No links found.
Add New Link
In order to write a comment you must first login.
Login or Register (for free!)
Add Link
|
$0.00
1/1/0001 12:00:00 AM
Sponsors
|